Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia

Sevinc, Alper; ÖZKAN, METİN; Ozet, Ahmet; DANE, FAYSAL; Oksuzoglu, Berna; Isikdogan, Abdurrahman; ÖZDEMİR, FEYYAZ; Uncu, Dogan; GÜMÜŞ, MAHMUT; EVRENSEL, TÜRKKAN; YAREN, ARZU; Kara, Oguz; TEKİN, Salim

doi:10.2147/ott.s106342

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia

Sevinc A., ÖZKAN M., Ozet A., DANE F., Oksuzoglu B., Isikdogan A., ...Daha Fazla

ONCOTARGETS AND THERAPY, cilt.11, ss.419-426, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 11
Basım Tarihi: 2018
Doi Numarası: 10.2147/ott.s106342
Dergi Adı: ONCOTARGETS AND THERAPY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.419-426
Anahtar Kelimeler: chemotherapy, febrile neutropenia, neutrophil, ANC recovery, supportive care, myelosuppressive, COLONY-STIMULATING FACTOR, NON-HODGKINS-LYMPHOMA, FEBRILE NEUTROPENIA, G-CSF, RECEIVING CHEMOTHERAPY, CANCER-CHEMOTHERAPY, BREAST-CANCER, LUNG-CANCER, RISK, CHOP
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim in patients with chemotherapy-induced neutropenia.